PACB Relative Valuation
PACB's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, PACB is overvalued; if below, it's undervalued.
Historical Valuation
Pacific Biosciences of California Inc (PACB) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -6.54. The fair price of Pacific Biosciences of California Inc (PACB) is between NaN to NaN according to relative valuation methord.
Relative Value
Fair Zone
NaN-NaN
Current Price：2.47
Fair
-4.57
PE
1Y
3Y
5Y
Trailing
Forward
-8.47
EV/EBITDA
Pacific Biosciences of California Inc. (PACB) has a current EV/EBITDA of -8.47. The 5-year average EV/EBITDA is -12.36. The thresholds are as follows: Strongly Undervalued below -36.32, Undervalued between -36.32 and -24.34, Fairly Valued between -0.38 and -24.34, Overvalued between -0.38 and 11.60, and Strongly Overvalued above 11.60. The current Forward EV/EBITDA of -8.47 falls within the Historic Trend Line -Fairly Valued range.
-6.95
EV/EBIT
Pacific Biosciences of California Inc. (PACB) has a current EV/EBIT of -6.95. The 5-year average EV/EBIT is -11.03. The thresholds are as follows: Strongly Undervalued below -32.24, Undervalued between -32.24 and -21.64, Fairly Valued between -0.43 and -21.64, Overvalued between -0.43 and 10.17, and Strongly Overvalued above 10.17. The current Forward EV/EBIT of -6.95 falls within the Historic Trend Line -Fairly Valued range.
4.28
PS
Pacific Biosciences of California Inc. (PACB) has a current PS of 4.28. The 5-year average PS is 15.01. The thresholds are as follows: Strongly Undervalued below -14.27, Undervalued between -14.27 and 0.37, Fairly Valued between 29.65 and 0.37, Overvalued between 29.65 and 44.29, and Strongly Overvalued above 44.29. The current Forward PS of 4.28 falls within the Historic Trend Line -Fairly Valued range.
-8.82
P/OCF
Pacific Biosciences of California Inc. (PACB) has a current P/OCF of -8.82. The 5-year average P/OCF is -15.33. The thresholds are as follows: Strongly Undervalued below -53.78, Undervalued between -53.78 and -34.56, Fairly Valued between 3.89 and -34.56, Overvalued between 3.89 and 23.12, and Strongly Overvalued above 23.12. The current Forward P/OCF of -8.82 falls within the Historic Trend Line -Fairly Valued range.
-7.26
P/FCF
Pacific Biosciences of California Inc. (PACB) has a current P/FCF of -7.26. The 5-year average P/FCF is -17.52. The thresholds are as follows: Strongly Undervalued below -106.69, Undervalued between -106.69 and -62.11, Fairly Valued between 27.07 and -62.11, Overvalued between 27.07 and 71.66, and Strongly Overvalued above 71.66. The current Forward P/FCF of -7.26 falls within the Historic Trend Line -Fairly Valued range.
Pacific Biosciences of California Inc (PACB) has a current Price-to-Book (P/B) ratio of 20.32. Compared to its 3-year average P/B ratio of 3.62 , the current P/B ratio is approximately 461.47% higher. Relative to its 5-year average P/B ratio of 6.57, the current P/B ratio is about 209.27% higher. Pacific Biosciences of California Inc (PACB) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -30.27%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -20.64% , the current FCF yield is about -100.00% lower.
21.08
P/B
Median3y
3.62
Median5y
6.57
-17.21
FCF Yield
Median3y
-30.27
Median5y
-20.64
Competitors Valuation Multiple
The average P/S ratio for PACB's competitors is , providing a benchmark for relative valuation. Pacific Biosciences of California Inc Corp (PACB) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of -3.82%, this premium appears unsustainable.
P/S
P/E
EV/EBITDA
EV/EBIT
P/S
Revenue Growth
Market Cap
Performance Decomposition
1Y
3Y
5Y
Market capitalization of PACB increased by 37.70% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -0.84 to -1.48.
The secondary factor is the Revenue Growth, contributed -3.82%to the performance.
Overall, the performance of PACB in the past 1 year is driven by P/E Change. Which is more unsustainable.
People Also Watch
FAQ
Is Pacific Biosciences of California Inc (PACB) currently overvalued or undervalued?
What is Pacific Biosciences of California Inc (PACB) fair value?
How does PACB's valuation metrics compare to the industry average?
What is the current P/B ratio for Pacific Biosciences of California Inc (PACB) as of Dec 05 2025?
What is the current FCF Yield for Pacific Biosciences of California Inc (PACB) as of Dec 05 2025?
What is the current Forward P/E ratio for Pacific Biosciences of California Inc (PACB) as of Dec 05 2025?